Low mortality of Omicron? The Yearbook of oncology says that the mortality rate of breakthrough infection in cancer patients is 13%
Recently, European and American countries often use “Omicron mortality is very low” as self comfort. Is it feasible? In December 24th, the oncology Yearbook warned that cancer patients who are high-risk groups, even if they are vaccinated completely, will have a mortality rate of 13% after COVID-19 breakthrough infection.
Novel coronavirus pneumonia is the first clinical study in the world to get a breakthrough infection in patients with completely vaccinated cancer. The new alliance is led by the new crown hair coloring Cancer Coalition. A joint team of 129 research centers has conducted a follow-up survey of the incidence of cancer patients. The novel coronavirus pneumonia is a high-risk group of Toni Choueiri, director of the Lanke urogenital health center at Dana Farber Cancer Institute. Previous studies have shown that after vaccination, the serum conversion rate of patients is significantly lower, especially in patients with blood tumors, which is lower than that of patients with solid cancer, and there are still serious hidden dangers of infection.
Patients with cancer and other immunosuppressive treatments were excluded from the clinical study of new crown vaccine, and there were few relevant clinical data before. However, considering that cancer patients are the weak in the epidemic, and the immune response after vaccination is less than that of ordinary people, further follow-up investigation on the infection risk of this group is needed.
Novel coronavirus pneumonia has been authorized by the Pfizer, Moderna and Johnson vaccines since November last year. The study collected data from 1787 patients with newly diagnosed pneumonia who had cancer combined with cancer from November 1, 2020 to May 2021 31, of whom 1656 (97%) were not vaccinated, 77 (4%) were vaccinated partially, and 54 (3%) were vaccinated completely. The lymphocyte level decreased in 46% of the fully vaccinated patients. The incidence of lymphocyte level reduction was the highest in patients receiving anti-CD20 monoclonal antibody or car-t cells for the treatment of hematological malignancies, including lymphoma and leukemia. The effect of vaccination was relatively poor in these patients.
The results showed that 7 people died (13%), 10 people were treated in ICU (19%) and 35 people were hospitalized (65%) in the complete vaccination group. The death rate was higher than that in the non vaccination group. Considering that the incidence of blood tumors in the complete vaccination group is higher and their immunity is relatively worse, after data balance, it can be concluded that the protection against death of cancer patients fully vaccinated is 8% higher than that of non vaccinated patients, while the protection against ICU treatment is 13%, which has no statistical difference.
The study also showed that the delta variant appeared in the second quarter of 2021 showed a higher transmission risk than the original strain, including reduced vaccine immunity, a higher proportion of breakthrough infection and a greater threat to the life safety of cancer patients.
Choueiri concluded that in the process of practical application, doctors do not routinely collect patients’ immune indicators, so they do not know whether they have produced an effective immune response. However, practical data show that cancer patients, especially patients with blood tumors, fail to produce sufficient immunity.
Even if cancer patients are fully vaccinated, breakthrough infection will still lead to serious consequences, including death. Other immunocompromised groups such as organ transplant recipients also showed similar results. Therefore, public health and epidemic prevention suggestions such as masks and social distance are still essential to them.
It is noteworthy that the emergence of delta virus in the research process confirmed the risk of virus immune escape and breakthrough infection. Omicron has shown stronger immune escape ability than Delta, and the risk of breakthrough infection has further increased. Cancer patients, other immunosuppressive patients and close contacts should become an important target group for treatment and prevention intervention.
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer